Quantcast

HuTARG(TM) Technology Delivers High Affinity Fully Human Antibody Therapeutics

February 18, 2014

BURNABY, BC, Feb. 18, 2014 /PRNewswire/ – Innovative Targeting Solutions Inc.
(ITS) a pioneer in novel protein engineering technologies, today
announced the successful application of the company’s proprietary
affinity maturation technology for the purposes of generating
antibodies with pM affinities. These first in class antibodies are
unique in that all mutations are specifically targeted to CDRs, unlike
error prone PCR, somatic hypermutation or other traditional mutagenesis
approaches, leaving the antibody frameworks in germline
configuration. Because the diversity is generated de novo, in vitro,
by the HuTARG(TM) cell line itself, there are no manipulations of large
recombinant libraries nor challenges due to the lower transformation
rates of mammalian cells. The HuTARG(TM) technology coupled with
Fluorescence Activated Cell Sorting (FACS) allows for the straight
forward isolation of antibodies with ten up to several hundred fold
increases in affinity in a single FACS run and over a thousand fold
increase in affinity in two rounds of CDR optimization. In addition,
the HuTARG(TM) Technology avoids the loss of time and labour involved in
reformatting; as a mammalian platform it allows for the simultaneous
selection of high expressing antibodies and does not advance antibodies
with mutations that would only later be discovered to have adversely
affected manufacturability.

“Our generation of subnanomolar affinity antibodies is the last critical
set of data validating the HuTARG(TM) technology. The technology not only
generates large repertoires of fully human antibodies but can also be
used to precisely target mutations to generate antibodies with improved
characteristics. We anticipate that 2014 will be a transforming year
for the company; we are in late stage discussions with several
pharmaceutical companies interested in internalizing our HuTARG(TM)
technology , we have a paradigm shifting solution for generating high
quality protein based therapeutics, and a novel first-in-class drug
candidate in early development.” -Michael Gallo, President, Innovative
Targeting Solutions Inc.

About Innovative Targeting Solutions Inc.

Founded in 2008, Innovative Targeting Solutions Inc. is a privately held
company that has developed the HuTARG(TM) technology, a next generation
protein engineering platform for the generation and maturation of fully
human antibody therapeutics. The HuTARG(TM) technology is a fully
mammalian technology that generates antibody diversity in vitro via
RAG1/RAG2 mediated V(D)J recombination. For more information please
visit www.innovativetargeting.com

SOURCE Innovative Targeting Solutions Inc


Source: PR Newswire



comments powered by Disqus